Li, Fuhui
Qin, Tiejun
Li, Bing http://orcid.org/0000-0002-8291-9883
Qu, Shiqiang
Pan, Lijuan
Zhang, Peihong
Sun, Qi
Cai, Wenyu http://orcid.org/0000-0002-7550-8832
Gao, Qingyan
Jiao, Meng
Li, Junjie
Ai, Xiaofei
Ma, Jiao
Gale, Robert Peter
Xu, Zefeng http://orcid.org/0009-0001-0147-2291
Xiao, Zhijian http://orcid.org/0000-0002-1099-4489
Article History
Received: 6 February 2024
Revised: 19 April 2024
Accepted: 23 April 2024
First Online: 7 May 2024
Competing interests
: RPG is a consultant to NexImmune Inc, Nanexa Pharma, Ascentage Pharm Group and Antengene Biotech LLC. He is Medical Director of FFF Enterprises Inc., Partner in AZAC Inc., is on the Board of Directors of the Russian Foundation for Cancer Research Support and is a member of the Scientific Advisory Board of StemRad Ltd. The other authors have no relevant conflicts of interest to declare about the manuscript.
: The patient gave written informed consent compliant with the Declaration of Helsinki.